A novel small molecule inhibitor (Bufotalin) of GPX4 was recently reported to induce GPX4 ubiquitination and degradation, lipid peroxidation, and ferroptosis, and thus could serve as potential anti-tumor agents (Zhang et al. 2022). This evidence concerns the gene GPX4 and neoplasm.